CAJ | 학술논문

目的分析恶性血液疾病异基因造血干细胞移植(allo-HSCT)治疗的危险因素,探索中国人群EBMT积分预测移植长期疗效的临床意义.方法回顾性分析144例allo-HSCT治疗的血液病患者,预后评估参照EBMT积分,危险因素包括患者年龄、疾病状态、诊断至移植时间、供/患者性别组合、供体来源.将患者分为3组:低危组(0～1分)、中危组(2～3分)和高危组(4～7分).结果移植后所有患者的中位随访时间为413(10～1827)d,存活患者中位随访837(166～ 1827)d,预期4年总生存(OS)率、移植相关死亡率(TRM)及复发率(RR)分别为(57.5±4.6)％、(21.6±3.7)％和(42.7士6.1)％.其中低危组4年OS率、TRM 、RR分别为(72.2±9.0)％、(8.1士4.5)％和(27.3士8.7)％,明显优于中危组[分别为(57.7士6.0)％、(23.1±5.1)％和(44.9±8.3)％]和高危组[分别为(36.9士10.2)％、(33.5±9.2)％、(51.5±11.8)％],差异具有统计学意义(P值分别为＜0.01、0.02和0.009).结论 EBMT积分体系能有效提示allo-HSCT治疗恶性血液病的OS率、TRM和RR.
목적 분석악성혈액질병이기인조혈간세포이식(allo-HSCT)치료적위험인소,탐색중국인군EBMT적분예측이식장기료효적림상의의.방법 회고성분석144례allo-HSCT치료적혈액병환자,예후평고삼조EBMT적분,위험인소포괄환자년령、질병상태、진단지이식시간、공/환자성별조합、공체래원.장환자분위3조:저위조(0～1분)、중위조(2～3분)화고위조(4～7분).결과 이식후소유환자적중위수방시간위413(10～1827)d,존활환자중위수방837(166～ 1827)d,예기4년총생존(OS)솔、이식상관사망솔(TRM)급복발솔(RR)분별위(57.5±4.6)％、(21.6±3.7)％화(42.7사6.1)％.기중저위조4년OS솔、TRM 、RR분별위(72.2±9.0)％、(8.1사4.5)％화(27.3사8.7)％,명현우우중위조[분별위(57.7사6.0)％、(23.1±5.1)％화(44.9±8.3)％]화고위조[분별위(36.9사10.2)％、(33.5±9.2)％、(51.5±11.8)％],차이구유통계학의의(P치분별위＜0.01、0.02화0.009).결론 EBMT적분체계능유효제시allo-HSCT치료악성혈액병적OS솔、TRM화RR.
Objective To evaluate the impact of EBMT score system in patients with hematological malignancies received allogeneic hematopoietic stem cell transplantation (allo-HSCT).Methods A total of 144 consecutive patients were analyzed retrospectively.According to the EBMT score system,including age,disease status before transplantation,interval between diagnoses to transplantation,donor/recipient sex match and donor type,patients were divided into 3 risk groups:low risk (score 0-1),intermediate risk (score 2-3) and high risk (score 4-7).Results The median follow-up duration were 413 (10-1827) days for all patients and 837 (166-1827) days for alive patients.The estimated 4-year overall survival (OS),transplant-related mortality (TRM) and relapse rate (RR) were (57.5±4.6)％,(21.6±3.7)％ and (42.7±6.1)％,respectively.The 4-year OS,TRM and RR were (72.2±9.0)％,(8.1±4.5)％ and (27.3±8.7)％ in the low-risk group,significantly superior to both intermediate-risk group [(57.7±6.0)％,(23.1 ±5.1)％ and (44.9±8.3)％]and high-risk group [(36.9±10.2)％,(33.5±9.2)％ and (51.5±11.8)％] (P＜0.01,0.02 and 0.009 for OS,TRM and RR respectively).Conclusion The EBMT score system provides prognostic significance for OS,TRM and RR in patients with hematological malignancies received allo-HSCT.